Mental Health Changes in Adolescents and Adults With Cystic Fibrosis After Initiation of Elexacaftor/Tezacaftor/Ivacaftor Therapy
Authors:
- Els van der HeijdenEHEls van der Heijden
- Rutger M. van Den BorRBRutger M. van Den Bor
- Marlou C. BierlaaghMBMarlou C. Bierlaagh
- Danya MuilwijkDMDanya Muilwijk
- Jessica M. de GraafJGJessica M. de Graaf
- Sanne L. NijhofSNSanne L. Nijhof
- Inez BronsveldIBInez Bronsveld
- Cornelis K. van der EntCECornelis K. van der Ent
- Sabine E.I. van der LaanSLSabine E.I. van der Laan
Open Access
- 7 February 2025
- journal article
- Published by Elsevier in CHEST Pulmonary
- Vol. 3 (3)
Abstract
No abstract availableFunding Information
- Nederlandse Cystic Fibrosis Stichting (R6266)
This publication has 30 references indexed in Scilit:
- Longitudinal Effects of Elexacaftor/Tezacaftor/IvacaftorChest, 2023
- Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftorPediatric Pulmonology, 2023
- Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosisJournal of Cystic Fibrosis, 2022
- Mental status changes during elexacaftor/tezacaftor / ivacaftor therapyJournal of Cystic Fibrosis, 2022
- Increasing life expectancy in cystic fibrosis: Advances and challengesPediatric Pulmonology, 2021
- Review of CFTR modulators 2020Pediatric Pulmonology, 2021
- A new era for people with cystic fibrosisEuropean Journal of Pediatrics, 2021
- Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosisInternational Forum of Allergy & Rhinology, 2020
- Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7)Journal of Affective Disorders, 2020
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006